Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2008

Plethora Could Earn up to $25M in Cash through Financing Deal with Paul Capital Healthcare

  • Plethora Solutions reports that it could receive up to $28 million in cash through a revenue interest financing agreement with Paul Capital Healthcare. The funding will go toward advancement of the firm’s erectile dysfunction and premature ejaculation programs.

    Plethora will get $15 million with signature of this agreement. Another $10 million will be paid only upon the first U.S. commercial sale of the firm’s late-stage compound for premature ejaculation, PSD502. In addition, Plethora has the option to have Paul Capital Healthcare invest $3 million this year through an equity subscription.

    In return, Paul Capital Healthcare will receive interest on revenues generated from Plethora's male health portfolio. The revenue interest will come primarily from sales of ErecAid, PSD502, and PSD510. ErecAid is marketed by Plethora's subsidiary, Timm Medical, for the treatment of erectile dysfunction. PSD510 is reportedly in Phase III development for erectile dysfunction.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »